Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
23.30
-0.64 (-2.67%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Aktis Oncology Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Aktis Oncology stock has a consensus rating of "Strong Buy" and an average price target of $35.39. The average 1-year stock price forecast is 51.89% higher than the current stock price, while the lowest is $31.5 (+35.19%) and the highest is $40 (+71.67%).
Price Target: $35.39 (+51.89%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Aktis Oncology stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 6 | 6 | 8 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 7 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $40 | Buy | Initiates | $40 | +71.67% | Sep 9, 2026 |
| Wedbush | Wedbush | Buy Initiates $35 | Buy | Initiates | $35 | +50.21% | Aug 19, 2026 |
| BMO Capital | BMO Capital | Buy Initiates $37 | Buy | Initiates | $37 | +58.80% | Aug 18, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $34 | Buy | Maintains | $34 | +45.92% | Aug 14, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Reiterates $33 | Buy | Reiterates | $33 | +41.63% | Aug 14, 2026 |
Financial Forecast
Revenue This Year
10.25M
from 6.50M
Increased by 57.73%
Revenue Next Year
9.67M
from 10.25M
Decreased by -5.65%
EPS This Year
-1.69
from -78.34
EPS Next Year
-2.15
from -1.69
EPS and Forward PE are based on non-GAAP adjusted numbers.